AIM
STAB

Advantage Investment Management’s Statera Biopharma, Inc. Common Stock STAB Stock Holding History

Advantage Investment Management’s Portfolio STAB Stock Details STAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-25
Closed – – 1135
2017
Q1 		$0 Hold
25
– – ﹤0.01% 1054
2016
Q4 		$0 Hold
25
– – ﹤0.01% 1033
2016
Q3 		$0 Hold
25
– – ﹤0.01% 982
2016
Q2 		$0 Hold
25
– – ﹤0.01% 942
2016
Q1 		$0 Hold
25
– – ﹤0.01% 944
2015
Q4 		$0 Hold
25
– – ﹤0.01% 908
2015
Q3 		$0 Hold
25
– – ﹤0.01% 918
2015
Q2 		$0 Hold
25
– – ﹤0.01% 929
2015
Q1 		$0 Hold
25
– – ﹤0.01% 906
2014
Q4 		$0 Buy
+25
New +$196 ﹤0.01% 796

Other funds holding STAB

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LTFS
Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
TDC
Thompson Davis & Co Richmond, Virginia $150M AUM 32.35% 1-Year Est. Return

Advantage Investment Management's STAB Position: Q2 2017 in Review

Advantage Investment Management sold out of Statera Biopharma, Inc. Common Stock (STAB) in Q2 2017, closing a stake of 25 shares.

Advantage Investment Management first reported a position in STAB in Q4 2014 and held it in 10 quarters. The position peaked at $0 in Q1 2017. 20 funds tracked by Wall St. Rank hold STAB as of Q2 2017.

  • Advantage Investment Management reported no remaining Statera Biopharma, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Advantage Investment Management sold 25 Statera Biopharma, Inc. Common Stock shares in Q2 2017.
  • Advantage Investment Management first reported a position in Statera Biopharma, Inc. Common Stock in Q4 2014 and held it in 10 quarters.
  • Advantage Investment Management's Statera Biopharma, Inc. Common Stock position peaked at $0 in Q1 2017.
  • 20 funds tracked by Wall St. Rank held Statera Biopharma, Inc. Common Stock as of Q2 2017.

Based on Advantage Investment Management's 13F filing for Q2 2017, filed 14 Aug 2017.